Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GETUG-AFU22: Degarelix + Radiotherapy vs Radiotherapy Alone for Detectable PSA After Prostatectomy
NCT01994239Phase 2Active, not recruiting
- Sponsor
- Unicancer
- Start
- Dec 2012
- Primary completion
- Mar 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of degarelix in prostate adenocarcinoma, sponsored by Unicancer. Started Dec 2012; status: active, not recruiting.
02
Drugs
degarelix
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT01994239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01994239.